The impact of liver resection on the dihydrouracil: uracil plasma ratio in patients with colorectal liver metastases
Jacobs, Bart A W; Snoeren, Nikol; Samim, Morsal; Rosing, Hilde; de Vries, Niels; Deenen, Maarten J; Beijnen, Jos H; Schellens, Jan H M; Koopman, Miriam; van Hillegersberg, Richard
(2018) European Journal of Clinical Pharmacology, volume 74, issue 6, pp. 737 - 744
(Article)
Abstract
PURPOSE: The dihydrouracil (DHU):uracil (U) plasma ratio is a promising marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient patients. The objective of this study was to determine the effect of liver resection on the DHU:U plasma ratio in patients with colorectal liver metastases (CRLM). METHODS: An observational study was performed in
... read more
which DHU:U plasma ratios in patients with CRLM were analyzed prior to and 1 day after liver resection. In addition, the DHU:U plasma ratio was quantified in six additional patients 4-8 weeks after liver resection to explore long-term effects on the DHU:U plasma ratio. Quantification of U and DHU plasma levels was performed using a validated ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assay. RESULTS: The median (range) DHU:U plasma ratio in 15 patients prior to liver resection was 10.7 (2.6-14.4) and was significantly reduced to 5.5 (< quantification limit (LLOQ-10.5) 1 day after resection (p = 0.0026). This reduction was caused by a decrease in DHU plasma levels from 112.0 (79.8-153) ng/mL to 41.2 (< LLOQ-160) ng/mL 1 day after resection (p = 0.0004). Recovery of the DHU:U plasma ratio occurred 4-8 weeks after liver resection, which was shown by a median (range) DHU:U plasma ratio in six patients of 9.1 (6.9-14.5). CONCLUSION: Liver resection leads to very low DHU:U plasma ratios 1 day after liver resection, which is possibly caused by a reduction in DPD activity. Quantification of the DHU:U plasma ratios directly after liver resection could lead to false-positive identification of DPD deficiency and is therefore not advised.
show less
Download/Full Text
An Open Access version of this item is not available due to the copyright policy of the publisher.
Keywords: Aged, Aged, 80 and over, Antimetabolites, Antineoplastic/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Bevacizumab/adverse effects, Capecitabine/adverse effects, Colorectal Neoplasms/blood, Female, Humans, Liver/surgery, Liver Neoplasms/blood, Male, Middle Aged, Organoplatinum Compounds/adverse effects, Oxaliplatin, Uracil/analogs & derivatives
ISSN: 0031-6970
Publisher: Springer
(Peer reviewed)
See more statistics about this item